stoxline Quote Chart Rank Option Currency Glossary
  
Janux Therapeutics, Inc. (JANX)
37.17  0.39 (1.06%)    02-13 16:00
Open: 37.07
High: 37.9
Volume: 598,086
  
Pre. Close: 36.78
Low: 36.17
Market Cap: 2,148(M)
Technical analysis
2025-02-13 4:49:05 PM
Short term     
Mid term     
Targets 6-month :  52.53 1-year :  59.44
Resists First :  44.98 Second :  50.89
Pivot price 40.77
Supports First :  35.41 Second :  29.46
MAs MA(5) :  37.45 MA(20) :  41.1
MA(100) :  49.83 MA(250) :  45.85
MACD MACD :  -3.2 Signal :  -3
%K %D K(14,3) :  9.6 D(3) :  5.9
RSI RSI(14): 35.6
52-week High :  71.7 Low :  8.94
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ JANX ] has closed above bottom band by 17.5%. Bollinger Bands are 19.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.94 - 38.08 38.08 - 38.25
Low: 35.78 - 35.94 35.94 - 36.11
Close: 36.88 - 37.13 37.13 - 37.42
Company Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Headline News

Thu, 13 Feb 2025
64,072 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Bought by abrdn plc - MarketBeat

Wed, 12 Feb 2025
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average PT from Analysts - MarketBeat

Sun, 09 Feb 2025
Andrew Hollman Meyer Sells 3,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - MarketBeat

Fri, 24 Jan 2025
Janux Therapeutics Appoints Former Amgen Director as Chief Medical Officer - StockTitan

Fri, 24 Jan 2025
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - Business Wire

Wed, 08 Jan 2025
Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 59 (M)
Held by Insiders 3.8e+007 (%)
Held by Institutions 7.2 (%)
Shares Short 6,410 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -8.388e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 164.4 %
Return on Equity (ttm) -10 %
Qtrly Rev. Growth 1.305e+007 %
Gross Profit (p.s.) -23.47
Sales Per Share -3.43
EBITDA (p.s.) -1.32869e+007
Qtrly Earnings Growth -1.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -37 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -10.86
Price to Cash Flow 10.43
Stock Dividends
Dividend 0
Forward Dividend 8.55e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android